Find a Clinical Trial

Researchers all over Australia and New Zealand are running clinical trials for people at different ages and stages of type 1 diabetes. Use our clinical trial finder below to find clinical trials near you.

Tailor your results by using the filters below

Baricitinib in New Onset Type 1 Diabetes (BANDIT)

BANDIT is a clinical trial testing a drug called baricitinib that has the potential to slow or stop the destruction of beta cells in people with T1D.

Participants in the BANDIT trial must be between the ages of 10 – 30 years old, and must have been diagnosed with type 1 diabetes within the last 100 days.

Participants will be required to attend at one of four sites in Melbourne or Adelaide: The Royal Melbourne Hospital, The Royal Children’s Hospital, St Vincent’s Hospital Melbourne or the Women’s and Children’s Hospital Adelaide.

BANDIT has been approved by the Melbourne Health Human Research Ethics Committee (HREC).

ANZCTR listing: ACTRN12620000239965

Learn More

KEY REQUIREMENTS

Location VIC, SA

Age 10-30 years

T1D diagnosis within the last 100 days

Managing Type 1 Diabetes During Exercise in High-Level Athletes

Regular exercise is a cornerstone for managing type 1 diabetes (T1D), but many people with T1D face obstacles that stop them meeting physical activity guidelines.

However, athletes with T1D are highly proficient at managing their condition within the context of their sport. For this reason, their strategies may offer valuable lessons for managing blood glucose levels during exercise.

The aim of this study is to describe the strategies used by competitive athletes with T1D to successfully manage their condition during sport and exercise.

The study involves a 45 minute survey that will explore your strategies for managing blood glucose levels during exercise. Specifically, you will be asked questions about training and competition, your diabetes management, and strategies you believe are important to your success as a high-level athlete with T1D. This can be done either in person, over the phone, or using video conferencing software (e.g., WebEx, Microsoft Teams), alternatively you may submit written responses to an online survey.

For more information, please contact Shania Smee shania.smee@student.curtin.edu.au

KEY REQUIREMENTS

Location NSW, ACT, NT, QLD, SA, TAS, VIC, Virtual, WA

Age 13-60

Diagnosed with type 1 diabetes

High-level athletes competing at a state, national or international level

Physical Activity Levels in Secondary School Students with T1D

Regular exercise is important for health and has additional health benefits for children with type 1 diabetes, including improvements in mental health and reduced cardiovascular disease risk factors. 

Despite the benefits of exercise, research shows that high school aged adolescents with type 1 diabetes may experience additional barriers to exercise, including fear of hypoglycaemia or loss of control of diabetes. Some research also shows that youth with type 1 diabetes do less exercise than their peers without diabetes.

This is an important study that will identify barriers to exercise in high school aged youth with type 1 diabetes, and compare the amount of exercise adolescents with type 1 diabetes do to their peers without diabetes.

The study will help to inform interventions to support youth with type 1 diabetes to be more physically active and improve their health.

For more information, please contact Dr Carmel Smart Carmel.Smart@hnehealth.nsw.gov.au

This study has Human Research Ethics Committee (HREC) approval from Hunter New England Research Ethics Committee.

KEY REQUIREMENTS

Location NSW

Age 12 - 17

Young people with T1D aged 12-17 years

Diagnosed with T1D for > 6 months

Attend high school in the Hunter region of NSW

Sports Coaches Resources

One of the biggest challenges for young people participating in sport is when coaches do not know about or understand diabetes. The aim of this study is to work with young people with type 1 diabetes, parents and sports coaches to develop resources to educate coaches and support young people with type 1 diabetes to be physically active.  

The researchers will be conducting online interviews to find out about your experiences with your coaches and managing diabetes during sports.  

Interviews will be about one hour in length and will be online using Zoom. You will not need to attend Perth Children’s Hospital for any visits. 

For more information, contact Joanne O’Dea, Joanne.O’Dea@health.wa.gov   

This study has Human Research Ethics Committee (HREC) approval.

KEY REQUIREMENTS

Location WA

Age 8-21

Diagnosed with T1D for a minimum of 12 months

Participate in community sport

Parents of children who meet the criteria above

Exercise for Improving Hypoglycaemia Awareness

Researchers at the Children’s Diabetes Centre are looking to recruit individuals with Type 1 diabetes aged 14-35 years to assess whether a home-based program of either low-intensity or intermittent high-intensity exercise is practical, and can improve the ability to feel hypoglycaemic symptoms, in individuals with impaired hypoglycaemia awareness. 

For more information contact, Dr Mary Abraham diabetes.research@health.wa.gov.au

This study has Human Research Ethics Committee (HREC) approval.

Learn More

KEY REQUIREMENTS

Location WA

Age 14-35

People with T1D and impaired awareness of hypoglycaemia

Not currently participating in high-intensity exercise more than once per week

Own and use a phone with iOS (Apple) or Android operating system to use the app

Hydroxychloroquine in Individuals At Risk for Type 1 Diabetes

This clinical trial is testing a medication called hydroxychloroquine (HCQ) to assess safety and effectiveness in people at risk of developing T1D. The study is enrolling people with T1D autoantibodies confirmed by screening, to see if HCQ can prevent T1D developing.

HCQ is used as a treatment for malaria, lupus, and rheumatoid arthritis. It has also been used extensively for treatment of autoimmune disease in adults, children, and during pregnancy. This medication has not previously been studied as a treatment to prevent T1D.

If you’re interested in taking part, contact Leanne or Felicity at type1screen@mh.org.au, or call 03 9342 7063.

Learn More

KEY REQUIREMENTS

Location NSW, QLD, SA, VIC, WA

Age 3+ years

Two or more T1D-related autoantibodies (confirmed by screening)

Normal oral glucose tolerance test results within 7 weeks of starting study

Trialling a New App to Help Manage Glucose Levels During Exercise (acT1ve)

The current exercise guidelines for T1D vary and are challenging to follow.

We have been working with young people with T1D, other researchers and app developers to create a new smartphone exercise app called acT1ve.

The app asks the user questions about the activity they are going to do, and based on this information, gives insulin and carbohydrate advice for the activity. The advice is based on international exercise guidelines. We have tested acT1ve with a small group of young people with T1D to see what they thought about it and would now like to trial it with a larger number of young people to use at home while being active.

ANZCTR listing: ACTRN12620001066976

Learn More

KEY REQUIREMENTS

Location WA

Age 12-25 years

T1D diagnosis more than 6 months ago

Exercising regularly, or willing to start exercising

Own an iOS (Apple) or Android phone to use the app

INTIMET: Insulin Resistance in Type 1 Diabetes Managed with Metformin

Harmful patterns of insulin resistance in the muscle and liver may be an explanation for increased cardiovascular disease in T1D.

The INTIMET study is a detailed investigation of insulin resistance in T1D and will test if metformin can improve insulin action in muscle and the liver. Participants will be asked to take metformin (or placebo tablets) and are required to attend 4 appointments over 6 months at the Garvan Institute in Sydney.

This study is also recruiting people aged 20-50 without type 1 diabetes, who will attend 2 study visits but not receive medication.

ANZCTR listing: ANZCTR12619001440112

Learn More

KEY REQUIREMENTS

Location NSW

Age 20-50 years

T1D diagnosis more than 10 years ago

HbA1c <9.5%

Non-smoker

Cord Reinfusion in Diabetes (CORD) Pilot Study

Cell Care is partnering with The Children’s Hospital at Westmead, New South Wales, in a world–first study investigating the potential of cord blood to prevent or delay the onset of type 1 diabetes in children at high risk of developing the disease.

The CORD study has been approved by the Sydney Children’s Hospitals Network Human Research Ethics Committee.

ANZCTR listing: ACTRN12613000186752

Learn More

KEY REQUIREMENTS

Location NSW

Age 1-15 years

First- or second-degree relative with T1D

Children with stored cord blood, or parents expecting a child and planning cord blood storage

The Fenofibrate and Microvascular Events in Type 1 Diabetic Retinopathy (FAME-1-EYE) Study

This clinical trial is investigating whether fenofibrate, a drug used to lower cholesterol, can slow or reverse eye damage in adults with type 1 diabetes. Fenofibrate has been shown to slow eye damage in type 2 diabetes, and researchers are now investigating whether the same effect will be seen in T1D.

This study has been approved by the Northern Sydney Local Health District Human Research Ethics Committee.

ANZCTR listing: ACTRN12611000249954

Learn More

KEY REQUIREMENTS

Location NSW, QLD, SA, VIC, WA, New Zealand, Hong Kong

Age 18+ years

Non-proliferative diabetic retinopathy (NPDR)

ETDRS score 35-53

Nox 1/4 Inhibition to Treat Kidney Disease in Type 1 Diabetes

This study is testing whether a new tablet can help to treat kidney disease in people with T1D. This tablet blocks a key component of the pathway responsible for the oxidative stress that damages kidneys. Participants in this clinical trial will attend 10 study visits over 56 weeks.

This study has been approved by the South Metropolitan Health Service Human Research Ethics Committee.

For more information or to take part, contact crn@jdrf.org.au.

Learn More

KEY REQUIREMENTS

Location NSW, VIC, SA, WA, New Zealand

Age 18-70 years

HbA1c <10%

Albumin (protein) in the urine

Type1Screen: Screening for Type 1 Diabetes

Family members of people with T1D are at increased risk of developing the disease themselves.

Type1Screen is a free screening service available to any family member of a person with T1D, that can find out a person’s risk of developing T1D. Those at increased risk will be offered the opportunity to enrol in trials of new therapies that can potentially prevent T1D.

Learn More

KEY REQUIREMENTS

Location ACT, NSW, NT, QLD, SA, TAS, VIC, WA, New Zealand

Age 2-30 years

Have a relative diagnosed with T1D or have previously had a positive antibody test

Have access to a pathology collection centre

Advanced hybrid closed-loop technology for young people with T1D

Our researchers are looking for young people with type 1 diabetes with a HbA1c above 9% to be involved in a clinical trial of a new advanced hybrid closed-loop system.

We want to see if using the closed-loop insulin delivery system will improve time in range and HbA1c in this group.

Learn More

KEY REQUIREMENTS

Location NSW, SA, VIC, WA

Age 12-25 years

Using an insulin pump already

Having your past 2 HbA1c readings above 9%

 

Become a game changer.

Get the latest research updates straight to your inbox and be the first to hear about new clinical trials.

Please enter your details

Researchers: is your T1D clinical trial not displayed here?

Submit a trial